<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00184600 on 2008_02_14: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00184600">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00184600">&#8593; Current version of this study</a></div><h1>View of NCT00184600 on
  2008_02_14</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00184600</td>
</tr>
<tr>
<th>Updated:</th><td>2008_02_14</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>3 Year Efficacy and Safety Comparison of Adding Insulin Detemir, Biphasic Insulin Aspart 30 or Insulin Aspart to Oral Antidiabetic Drug Treatment in Type 2 Diabetes.</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>This trial is conducted in Europe.<br>
<br>
<br>
<br>The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD treatment in type 2 diabetes and to verify the safety of use ( number and severity of episodes of hypoglycaemia, body weight and side effects).</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Active Control</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Proportion of subjects who achieve HbA1c = 6.5% without hypoglycaemia<br>Time Frame: in the last 4 weeks of year 1/year 3<br>Safety Issue? No</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: Efficacy and durability of the insulin regimens<br>Time Frame: over a 12-36 months following a treatment algorithm<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Adverse events<br>Time Frame: during treatment<br>Safety Issue? Yes</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: body weight<br>Time Frame: after 52 or 156 weeks of treatment<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Quality of Life<br>Time Frame: after 52 or 156 weeks of treatment<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Blood glucose<br>Time Frame: after 52 or 156 weeks of treatment<br>Safety Issue? No</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Hypoglycaemia<br>Time Frame: during treatment<br>Safety Issue? Yes</td>
</tr>
<tr>
<th>Condition</th><td>
         Diabetes Mellitus, Type 2
      </td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: A      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Active Comparator</div>
<p></p>
</td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: B      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Active Comparator</div>
<p></p>
</td>
</tr>
<tr>
<th>Arm/Group</th><td>
<div>Arm Label: C      
            &nbsp; &nbsp; &nbsp; &nbsp;
        Active Comparator</div>
<p></p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: biphasic insulin aspart
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: B</div>
<p>Treat-to-target, s.c. injection, twice daily plus option for insulin aspart</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: insulin detemir
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: A</div>
<p>Treat-to-target, s.c. injection, once or twice daily plus option for insulin aspart</p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: insulin aspart
            &nbsp; &nbsp; &nbsp; &nbsp;
            Arm Label: C</div>
<p>Treat-to-target, s.c. injection, three times a day plus option for insulin detemir</p>
</td>
</tr>
<tr>
<th>URL</th><td>http://novonordisk-trials.com</td>
</tr>
<tr>
<th>See also</th><td>
<p>Clinical Trials at Novo Nordisk</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Active, not recruiting</td>
</tr>
<tr>
<th>Start date</th><td>
         2004-11
      </td>
</tr>
<tr>
<th>Last follow-up date</th><td>
         2009-07
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         2009-07
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- Type 2 Diabetes<br> &nbsp;- Insulin naive<br> &nbsp;- On OAD treatment<br> &nbsp;- BMI = 40.0 kg/m2<br> &nbsp;- HbA1c7.0%-10% (both inclusive)<br>Exclusion Criteria:<br> &nbsp;- Proliferative retinopathy<br> &nbsp;- Recurrent major hypoglycaemia<br> &nbsp;- Cardial problems<br> &nbsp;- Uncontrolled hypertension<br> &nbsp;- Impaired hepatic or renal function</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>18 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Novo Nordisk</td>
</tr>
<tr>
<th>Organization study ID</th><td>NN304-1613</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Novo Nordisk
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Ireland: Irish Medicines Board
         </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United Kingdom: Medicines and Healthcare Products Regulatory Agency
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
